AR087363A1 - Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres - Google Patents
Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceresInfo
- Publication number
- AR087363A1 AR087363A1 ARP120102745A ARP120102745A AR087363A1 AR 087363 A1 AR087363 A1 AR 087363A1 AR P120102745 A ARP120102745 A AR P120102745A AR P120102745 A ARP120102745 A AR P120102745A AR 087363 A1 AR087363 A1 AR 087363A1
- Authority
- AR
- Argentina
- Prior art keywords
- diagnosis
- antibody
- canceres
- detection
- cxcr4
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513345P | 2011-07-29 | 2011-07-29 | |
| EP11306000 | 2011-07-29 | ||
| PCT/EP2012/064876 WO2013017562A1 (en) | 2011-07-29 | 2012-07-30 | Use of the antibody i-3859 for the detection and diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087363A1 true AR087363A1 (es) | 2014-03-19 |
Family
ID=47628653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102745A AR087363A1 (es) | 2011-07-29 | 2012-07-27 | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140170677A1 (OSRAM) |
| EP (1) | EP2736926A1 (OSRAM) |
| JP (1) | JP6138780B2 (OSRAM) |
| KR (1) | KR20140047127A (OSRAM) |
| CN (1) | CN103717620A (OSRAM) |
| AR (1) | AR087363A1 (OSRAM) |
| AU (2) | AU2012292116A1 (OSRAM) |
| BR (1) | BR112014001979A2 (OSRAM) |
| CA (1) | CA2842552A1 (OSRAM) |
| IL (1) | IL230693A0 (OSRAM) |
| MX (1) | MX2014001160A (OSRAM) |
| RU (1) | RU2636032C2 (OSRAM) |
| WO (1) | WO2013017562A1 (OSRAM) |
| ZA (1) | ZA201400500B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6232689B2 (ja) | 2015-06-25 | 2017-11-22 | 株式会社国際電気通信基礎技術研究所 | 多器官連関システムを基盤とした予測装置、及び予測プログラム |
| ES2837015T3 (es) * | 2015-10-23 | 2021-06-29 | Novartis Ag | Sistema de derivación de proximidades espaciales entre células |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN114778845A (zh) | 2016-03-29 | 2022-07-22 | 无限生物制药公司 | 药物组合物或食品组合物及评价活性成分体内效果的方法 |
| EP3438282A4 (en) | 2016-03-29 | 2020-05-06 | Advanced Telecommunications Research Institute International | METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| CN111465613A (zh) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | 癌症生物标志物及其使用方法 |
| US20210025895A1 (en) * | 2018-04-13 | 2021-01-28 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ507161A (en) * | 1998-03-30 | 2003-12-19 | Northwest Biotherapeutics Inc | Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis |
| AU2001258110B2 (en) | 2000-05-09 | 2006-10-19 | British Canadian Biosciences Corp. | Cxcr4 antagonist treatment of hematopoietic cells |
| CA2412436C (en) | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| AU2003232253A1 (en) * | 2003-05-02 | 2004-11-23 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| CA2597717C (en) * | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| AR063086A1 (es) * | 2006-10-02 | 2008-12-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos |
| EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
-
2012
- 2012-07-27 AR ARP120102745A patent/AR087363A1/es unknown
- 2012-07-30 JP JP2014522119A patent/JP6138780B2/ja not_active Expired - Fee Related
- 2012-07-30 BR BR112014001979A patent/BR112014001979A2/pt not_active IP Right Cessation
- 2012-07-30 CA CA2842552A patent/CA2842552A1/en not_active Abandoned
- 2012-07-30 US US14/235,235 patent/US20140170677A1/en not_active Abandoned
- 2012-07-30 WO PCT/EP2012/064876 patent/WO2013017562A1/en not_active Ceased
- 2012-07-30 EP EP12740374.9A patent/EP2736926A1/en not_active Ceased
- 2012-07-30 RU RU2014103054A patent/RU2636032C2/ru not_active IP Right Cessation
- 2012-07-30 KR KR1020147003605A patent/KR20140047127A/ko not_active Ceased
- 2012-07-30 MX MX2014001160A patent/MX2014001160A/es unknown
- 2012-07-30 CN CN201280037703.0A patent/CN103717620A/zh active Pending
- 2012-07-30 AU AU2012292116A patent/AU2012292116A1/en not_active Abandoned
-
2014
- 2014-01-22 ZA ZA2014/00500A patent/ZA201400500B/en unknown
- 2014-01-28 IL IL230693A patent/IL230693A0/en unknown
-
2017
- 2017-06-15 AU AU2017204043A patent/AU2017204043A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014103054A (ru) | 2015-09-10 |
| ZA201400500B (en) | 2014-11-26 |
| IL230693A0 (en) | 2014-03-31 |
| JP2014523920A (ja) | 2014-09-18 |
| CN103717620A (zh) | 2014-04-09 |
| AU2017204043A1 (en) | 2017-07-06 |
| US20140170677A1 (en) | 2014-06-19 |
| AU2012292116A1 (en) | 2014-02-06 |
| EP2736926A1 (en) | 2014-06-04 |
| JP6138780B2 (ja) | 2017-05-31 |
| KR20140047127A (ko) | 2014-04-21 |
| BR112014001979A2 (pt) | 2017-02-21 |
| CA2842552A1 (en) | 2013-02-07 |
| RU2636032C2 (ru) | 2017-11-17 |
| MX2014001160A (es) | 2014-07-14 |
| WO2013017562A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087363A1 (es) | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| MX2020008976A (es) | Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1. | |
| GT201300276A (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b | |
| CL2016000883A1 (es) | Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma. | |
| MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
| EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| CL2018000270A1 (es) | Constructos de anticuerpo para cd70 y cd3. | |
| EA201491574A1 (ru) | Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car | |
| UY33647A (es) | ?agentes de unión a cd33?. | |
| MX365061B (es) | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| PE20151921A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| MX361058B (es) | Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero. | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
| MX372753B (es) | Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas. | |
| WO2012135340A3 (en) | Compositions and methods for diagnosing cancer | |
| CR20130657A (es) | Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo | |
| EA201591742A1 (ru) | Способ улучшения диагностики заболеваний с использованием измеряемых аналитов | |
| MX395376B (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MX350807B (es) | Composiciones y metodos para el analisis de cancer de prostata. | |
| MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
| EA201691091A1 (ru) | Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |